The company Evinova is using artificial intelligence (AI) to accelerate clinical trials with the aim of developing new drugs.
The application of this technology in the development of treatments seeks to reduce both the time and costs associated with researching therapeutic innovations. Backed by AstraZeneca and with strategic collaborations from Parexel and Fortrea, clinical trial management companies, Evinova aspires to become a leading provider of digital health solutions.
Evinova's solutions are based on science, evidence and human experience, offering services to clinical trial sponsors, clinical research organizations, care teams at clinical trial centers and patients.
The company prioritizes digital solutions already established and used at scale by AstraZeneca to optimize the design and conduct of clinical trials, which is expected to significantly reduce the time and economic costs of developing new drugs.
In addition to collaborating with Parexel and Fortrea, Evinova works with Accenture and Amazon Web Services to accelerate industry adoption and expand the global reach of its products.
Evinova's president, Cristina Durán, highlights the importance of this initiative in promoting the digital health sector and providing effective solutions to healthcare professionals, policymakers and patients.
AstraZeneca CEO Pascal Soriot emphasizes that the future of drug development can be accelerated through digital solutions.
Evinova is seeking options in remote patient monitoring and digital therapies, combining AstraZeneca's clinical and regulatory expertise with knowledge in digital technology, data science and artificial intelligence.
In the context of digital health, a growing market estimated at over 900 billion dollars by 2032, Evinova focuses on the 60% of the market related to R&D in digital health and care with remote patient monitoring.
It is noted that a significant portion of the cost and time of drug development is found in clinical trials, and Evinova seeks to improve the efficiency of this process.
The focus on digital health is also seen in other laboratories, such as Almirall, which has announced a collaboration agreement with Absci Corporation to discover, develop and commercialize therapies designed through artificial intelligence, especially targeting chronic and debilitating dermatological diseases.
Information from: merca2.
Receive all industry news in our weekly Scientific Dialectics newsletter.